Abstract: The present disclosure provides methods for minimizing oxidative damage in an animal or human during or after malnutrition, underfeeding or fasting, especially during refeeding after undernutrition or malnutrition, and for minimizing oxidant damage during or after toxicity resulting from chemotherapy, alcoholism, irradiation therapy or chemical or environmental exposure. The present methods comprise the step of administering an amount of keratinocyte growth factor effective for improving gut and/or systemic antioxidant status.

Abstract: Administration of a pharmaceutical composition comprising:(a) a vasodilator; and(b) a 15-hydroxyprostaglandindehydrogenase inhibitor is effective for the treatment of male erectile dysfunction.

Abstract: Selective blockade of DA and 5-HT uptake sites with 3-aryltropane derivatives.

Abstract: A composition and method for treating sexual dysfunction by natural means using a combination of L-arginine, ginseng and Zizyphi fructus in an orally administered dosage. The combination works synergistically to alleviate erectile dysfunction by stimulating enough release of NO in the corpus cavernosum to produce and sustain smooth muscle relaxation, thereby allowing the inflow of blood and alleviating erectile dysfunction. Thus, a natural medicinal alternative to Viagra.RTM. is provided for the treatment of erectile dysfunction. The composition and method is also useful in treating sexual conditions in females.

Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or-prophylaxis of obesity.

Abstract: Buprenorphine is a potent analgesic agent, it has been shown to be as effective as morphine. The main clinical application of buprenorphine is to relief postoperative pains or for patients in the terminal phase of cancer. The chance of becoming addiction and abuse is low, therefore it is pretty safe for clinical use. The half life of buprenorphine is short, since its hepatic extraction (extraction ratio is 0.7 to 0.9) and metabolism are high. For these reasons, oral administration of buprenorphine becomes impractical due to the need of giving drug frequiently. The present invention is related to enhancers used in transdermal preparations of narcotic analgesic agents. This invention employs pure components of Chinese herbs in a fixed ratio as transdermal penetration enhancers. Compositions of these transdermal preparations usually include 0.1 to 50% of narcotic analgesic agent, 0.

Abstract: Product containing tetrahydrolipstatin as the active ingredient and pharmaceutically acceptable excipients, characterized in that it is in the form of particles with a diameter of 0.25 to 2 mm; and pharmaceutical preparation s or compositions for oral administration containing the product.

Abstract: Disclosed are dopamine agonist and opioidergic compositions and methods for their use in the treatment of alcoholism. The invention discloses compounds and therapeutic kits useful in the treatment of alcoholics having the A1 allele of the dopamine receptor D2 gene. Also disclosed are methods of treating alcoholics having the A1/A1 or A1/A2 DRD2 genotype comprising administration of dopamine agonists such as aporphines, ergolines, related compounds, and their analogs, in combination with opioidergic compounds such as naloxone.

Abstract: The present investigation relates to the use of a local anesthetic for the manufacture of a medicament for use against infertility or for increasing fertility. It also relates to a pharmaceutical composition comprising a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. It also relates to a process for increasing fertility in a woman with said pharmaceutical composition.

Abstract: A therapeutic method is provided to manage human body weight in nicotine-experienced or nicotine-naive individuals, comprising of transdermally administering an amount of nicotine metabolites or a pharmaceutically acceptable salts thereof to a human in need of such treatment, in an amount which is effective to manage human body weight.

Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.

Abstract: A method of treating osteoporosis is disclosed by administering orally a single daily dosage of phosphate in the evening in an amount, e.g., about 10 mg/kg body weight or less which is effective to raise serum parathyroid hormone levels of the subject being treated.

Abstract: Oral antitussive pharmaceutical composition which allows a significant contact of its components with mucous membranes of the buccal cavity and comprises a centrally acting antitussive or a pharmaceutically acceptable salt thereof and benzydamine or a pharmaceutically acceptable acid addition salt thereof.

Abstract: Galanthamine and the pharmaceutically suitable acid addition salts thereof can be used for the treatment of alcoholism; these compounds are released from adequate pharmaceutic formulations which are administered, e.g., orally, transdermally, or otherwise parenterally, in a continuous and controlled manner.

Abstract: This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia iervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation;R.sub.1 is hydrogen or alkyl;R.sub.2 is alkyl;R.sub.4 is hydrogen, alkyl, formyl, or alkanol;R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, aakyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;R.sub.7 is hydrogen or alkyl; andn is 0, 1, 2, 3, or 4;or a pharmaceutically acceptable salt thereof.

Abstract: The compositions and methods of the invention provide a convenient means for systemically administering an integrin receptor antagonist or a pharmaceutically effective amount thereof to a patient by introducing the antagonist, in an ophthalmic formulation, to the patient's eye.

Abstract: The present invention relates to a therapeutic composition comprising an aqueous solution of at least one polymer and at least one electrolyte, wherein the aqueous solution is preferably buffered and optionally contains at least one mucin. The polymer can be chosen for instance from the group which consists of scleroglucan, guar gum, xanthane gum, sodium carboxymethyl cellulose, hydroxyethyl cellulose, polyacrylic acid and polyvinyl alcohol. The therapeutic composition according to the invention can serve as saliva substitution agent, artificial tear water, in a mouth rinse or in a toothpaste.

Abstract: A wound-healing preparation comprises a solution or paste of a non-reducing sugar and iodine in a vehicle consisting essentially of a pharamcologically acceptable glycol, especially glycerol, and, optionally, water. Preferably, the sugar is sucrose, especially that obtained from sugar beet, and the vehicle is substantially anhydrous glycerol. In one preferred embodiment, the preparation is in the form of a veterinary infusible solution and is particularly useful in the treatment of mastitis. In another embodiment, surgical sutures are treated by coating with the preparation to prevent the presence or abscesses around surgical suture lines.

Abstract: The present invention provides novel compounds such as certain aryloxy indanamines which are useful as anti-depressants and as inhibitors of synaptic norepinephrine and serotonin uptake. The present invention also provides an improvement in the treatment of depression which comprises inhibiting synaptic serotonin and epinepherine uptake.

Abstract: The present invention relates to a treatment for patients having urinary incontinence by administering a composition comprising histamine, serotonin or a combination thereof in an amount effective to alleviate symptoms of urinary incontinence.